After H.C. Wainwright and RBC Capital gave Aptose Biosciences (NASDAQ: APTO) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Matthew Biegler maintained a Buy rating on Aptose Biosciences today. The company’s shares opened today at $2.19.
Biegler has an average return of 14.2% when recommending Aptose Biosciences.
According to TipRanks.com, Biegler is ranked #2534 out of 5249 analysts.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.25, a 231.1% upside from current levels. In a report issued on March 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.55 and a one-year low of $1.57. Currently, Aptose Biosciences has an average volume of 271.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806 a non-covalent small molecule therapeutic agent.
